February 12, 2008 - Accuray Inc. today announced that two- and thee-year studies on its Cyberknife radiosurgery has shown no side effects on men treated for prostate cancer and prostate specific antigen (PSA) levels showed sustained reduction during the studies.
These findings were shared at the 7th Annual CyberKnife Users' Meeting, which was held Jan. 23-27, 2008 in Scottsdale, AR.